<DOC>
	<DOC>NCT01821781</DOC>
	<brief_summary>This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce graft rejection and optimize donor cell engraftment.</brief_summary>
	<brief_title>Immune Disorder HSCT Protocol</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Granulomatous Disease, Chronic</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>DiGeorge Syndrome</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<mesh_term>Autoimmune Lymphoproliferative Syndrome</mesh_term>
	<mesh_term>Chediak-Higashi Syndrome</mesh_term>
	<mesh_term>Genetic Diseases, X-Linked</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>&lt;/= 21 years of age Performance status &gt;/= 40 DLCO &gt;/= 40% LVEF &gt;/=40% or LVSF &gt;/=26% Serum creatinine &lt; 2x ULN Liver enzymes &lt;/= 5x ULN Negative pregnancy test Suitably matched donor (6/6 matched sib UCB, 8/8 matched sib BM or PBSC, 56/6 matched unrelated UCB, 78/8 matched unrelated BM, double cord) Known diagnosis of HIV I/II Pregnant or breastfeeding Uncontrolled invasive fungal or bacterial infections within 1 month prior to starting alemtuzumab Uncontrolled viral infection within 1 week prior to starting alemtuzumab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Immune deficiency</keyword>
	<keyword>Immune disorders</keyword>
	<keyword>Immune dysregulatory</keyword>
	<keyword>Reduced Intensity</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Campath</keyword>
</DOC>